Iambic Therapeutics' Co-Founder and CEO on this month's $50M Series B Extension and the company's AI driven pipeline
Tom Miller describes the rationale for the raise and what it will allow Iambic to do, how he believes the company's AI approach is unique, the lead Her-2 program, and what's behind it.
Comments